Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Fibrosis severity and cirrhosis drive patient-reported outcomes with NASH
Key clinical point: Patient-reported outcomes were significantly worse in NASH patients with cirrhosis than those with fibrosis.
Major finding: Patients with NASH and cirrhosis scored an average of 71.6 out of 100 on the role physical domain of the SF-36 vs. 75.4 for patients with NASH and bridging fibrosis.
Study details: The data come from 1,667 adults with NASH and bridging fibrosis or compensated cirrhosis.
Disclosures: The study was supported by Gilead Sciences. Dr. Younossi disclosed relationships with Gilead Sciences, as well as Intercept, NovoNordisk, BMS, Allergan/Tobira, Terns, Viking, AbbVie, Novartis, and Quest Diagnostics.
Younossi ZM et al. Clin Gastroenterol Hepatol. 2019. doi: 10.1016/j.cgh.2019.02.024.